~~<i id='46A4B02AA0'><strike id='46A4B02AA0'><tt id='46A4B02AA0'><pre id='46A4B02AA0'></pre></tt></strike></i>~~

Home» knowledge» comprehensive

comprehensive

author：entertainment 2025-10-04 08:18:46 Page View：968

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Studies point to risks of excluding people with obesity from drug trials
Next article： How one medical school became remarkably diverse

comprehensive

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Will Ozempic

Wegovy,theobesitydrug,wasinescapableattheObesityWeekconferenceinDallas.ElaineChenDALLAS—HereatObesit

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Hospital price transparency does save money, advocate argues

CynthiaFisher,founderandchairman,PatientRightsAdvocate.orgSTATBOSTON—Forallthosewhothinkhospitalpric